Lumefantrine

113 interactions 7 explained in plain English

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Acetaminophen And Codeine Levofloxacin Oxaliplatin Injection Aripiprazole Injection Flecainide Dolasetron

75 Major 38 Moderate

All (113) Major (75) Moderate (38)

Major

Lumefantrine Acetaminophen And Codeine Capital® & Codeine Explained Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Amitriptyline Elavil Explained Increased CYP2D6 substrates exposure and an increased risk of QT prolongation Details Lumefantrine Sertraline Explained An increased risk of QT interval prolongation Details Lumefantrine Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Lumefantrine Relugolix Orgovyx Explained Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy and an increa... Details Lumefantrine Trospium / Xanomeline Cobenfy Explained Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Lumefantrine Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Lumefantrine Aripiprazole Injection Abilify Increased CYP2D6 substrates exposure and an increased risk of QT prolongation Details Lumefantrine Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Lumefantrine Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Lumefantrine Azithromycin AzaSite Increased artemether/lumefantrine exposure and an increased risk of QT prolongation Details Lumefantrine Aficamten Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Alfuzosin UroXatral An increased risk of QT interval prolongation Details Lumefantrine Anagrelide Agrylin Increased risk of QT interval prolongation Details Lumefantrine Bedaquiline Sirturo An increased risk of QT interval prolongation Details Lumefantrine Brexpiprazole Rexulti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Chloroquine Aralen® An increased risk of QT interval prolongation Details Lumefantrine Dasatinib Phyrago An increased risk of QT interval prolongation Details Lumefantrine Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Lumefantrine Deutetrabenazine Austedo Increased CYP2D6 substrates exposure and an increased risk of QT prolongation Details Lumefantrine Disopyramide Norpace An increased risk of QT interval prolongation Details Lumefantrine Dofetilide Tikosyn An increased risk of QT interval prolongation Details Lumefantrine Dolasetron Anzemet An increased risk of QT interval prolongation Details Lumefantrine Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Lumefantrine Doxorubicin Adriamycin Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Encorafenib Braftovi Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine and loss of antimalarial efficacy and an inc... Details Lumefantrine Entrectinib Rozlytrek Increased artemether/lumefantrine exposure and an increased risk of QT prolongation Details Lumefantrine Eribulin Injection Halaven An increased risk of QT interval prolongation Details Lumefantrine Famotidine Calmicid An increased risk of QT interval prolongation Details Lumefantrine Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Lumefantrine Felbamate Felbatol An increased risk of QT interval prolongation Details Lumefantrine Flecainide Tambocor® Increased CYP2D6 substrates exposure and an increased risk of QT prolongation Details Lumefantrine Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Lumefantrine Fostemsavir Rukobia Increased risk of torsade de pointes Details Lumefantrine Galantamine Razadyne An increased risk of QT interval prolongation Details Lumefantrine Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Lumefantrine Gefitinib Iressa Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse reactions Details Lumefantrine Gemifloxacin Factive An increased risk of QT interval prolongation Details Lumefantrine Glasdegib Daurismo Increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.